CoChat

Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB P65 subunit

Open access
Wang, Xiaolei, Gao, Yanbin, Tian, Nianxiu, Zhu, Zhiyao, Wang, Tao, Xu, Jiayi, Wu, Bingjie, Zhang, Nan · 2018 · Drug Design, Development and Therapy

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

AIM: Mesangial cell (MC) activation plays an important role in many glomerular diseases associated with renal fibrosis, including diabetic kidney disease (DKD). The aim of this study was to determine whether Astragaloside IV (AS-IV) modulated MC activation in DKD via autophagy by specifically regulating the autophagy inducer sirtuin 1 (SIRT1). METHODS: Cultured MCs and diabetic KK-Ay mice were treated with AS-IV, and the markers and regulatory mediators of autophagy were analyzed using Western blotting, real-time PCR, ELISA and IF. RESULTS: AS-IV inhibited MC activation and enhanced autophagy in hyperglycemic conditions by increasing SIRT1 expression and decreasing NF-κB p65 acetylation. In addition, the SIRT1 activator SRT1720 enhanced autophagy and decreased p65 acetylation during hyperglycemia-induced MC activation. Opposite effects were seen with the SIRT1 inhibitor EX527. Furthermore, the ameliorative effect of AS-IV on MCs was abolished by the autophagy inhibitor 3-MA, while the autophagy activator rapamycin restored hyperglycemia-induced MC activation. Finally, AS-IV improved renal function and fibrosis in the diabetic KK-Ay mice. CONCLUSION: AS-IV ameliorated renal function and morphology by inducing autophagy and inhibiting MC activation through the SIRT1-NF-κB pathway, indicating a potential therapeutic role of AS-IV in glomerular diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s174058

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effect of AS-IV on hyperglycemia-induced activation of MCs. Notes: (A and B) CCK-8 assay results showed hyperglycemia increased the proliferation rate of MCs and that AS-IV decreased the proliferation rate of MCs treated with hyperglycemia for 48 hours in a dose-dependent manner. (C and D) Real-time PCR and Western blotting results showed AS-IV decreased the relative α-SMA levels in MCs exposed to hyperglycemia for 48 hours in a dose-dependent manner. (E and F) ELISA assay results showed AS-IV decreased the relative FN and Col IV levels in hyperglycemia-stimulated MCs for 48 hours in a dose-dependent manner. (G) Immunofluorescence images showed that the expression of α-SMA was increased in DKD group mice glomerulus compared with NC group mice glomerulus and that α-SMA expression was decreased in AS-IV group mice glomerulus. Blue, nuclear staining (DAPI); Green, target protein staining. Data are presented as mean ± SD. n=3. *Compared with NC, P<0.05; #Compared with HG, P<0.05. Abbreviations: AS-IV, Astragaloside IV; CCK-8, cell counting kit-8; DKD, diabetic kidney disease; HG, high glucose; MC, mesangial cell; NC, normal control.
Figure 1 Effect of AS-IV on hyperglycemia-induced activation of MCs. Notes: (A and B) CCK-8 assay results showed hyperglycemia increased the proliferation rate of MCs and that AS-IV decreased the proliferation rate of MCs treated with hyperglycemia for 48 hours in a dose-dependent manner. (C and D) Real-time PCR and Western blotting results showed AS-IV decreased the relative α-SMA levels in MCs exposed to hyperglycemia for 48 hours in a dose-dependent manner. (E and F) ELISA assay results showed AS-IV decreased the relative FN and Col IV levels in hyperglycemia-stimulated MCs for 48 hours in a dose-dependent manner. (G) Immunofluorescence images showed that the expression of α-SMA was increased in DKD group mice glomerulus compared with NC group mice glomerulus and that α-SMA expression was decreased in AS-IV group mice glomerulus. Blue, nuclear staining (DAPI); Green, target protein staining. Data are presented as mean ± SD. n=3. *Compared with NC, P<0.05; #Compared with HG, P<0.05. Abbreviations: AS-IV, Astragaloside IV; CCK-8, cell counting kit-8; DKD, diabetic kidney disease; HG, high glucose; MC, mesangial cell; NC, normal control.CC BY-NC · PubMed Central
Figure 2 Effect of AS-IV on SIRT1 and NF-κB p65 expression in hyperglycemia-induced MC activation in vitro. Notes: (A and B) Real-time PCR and Western blotting results showed that both SIRT1 activator SRT1720 and AS-IV increased the relative SIRT1 level in MCs exposed to hyperglycemia for 48 hours and that SIRT1 inhibitor EX527 abolished the change of AS-IV. (C and D) Real-time PCR and Western blotting results showed both SRT1720 and AS-IV decreased the relative p65 acetylation levels in MCs exposed to hyperglycemia for 48 hours and that EX527 increased the p65 acetylation levels. Data are presented as mean ± SD. n=3. *Compared with co-treated with hyperglycemia and AS-IV group, P<0.05; #Compared with HG group, P<0.05. Abbreviations: AS-IV, Astragaloside IV; HG, high glucose; MC, mesangial cell.
Figure 2 Effect of AS-IV on SIRT1 and NF-κB p65 expression in hyperglycemia-induced MC activation in vitro. Notes: (A and B) Real-time PCR and Western blotting results showed that both SIRT1 activator SRT1720 and AS-IV increased the relative SIRT1 level in MCs exposed to hyperglycemia for 48 hours and that SIRT1 inhibitor EX527 abolished the change of AS-IV. (C and D) Real-time PCR and Western blotting results showed both SRT1720 and AS-IV decreased the relative p65 acetylation levels in MCs exposed to hyperglycemia for 48 hours and that EX527 increased the p65 acetylation levels. Data are presented as mean ± SD. n=3. *Compared with co-treated with hyperglycemia and AS-IV group, P<0.05; #Compared with HG group, P<0.05. Abbreviations: AS-IV, Astragaloside IV; HG, high glucose; MC, mesangial cell.CC BY-NC · PubMed Central
Figure 3 Effect of AS-IV on SIRT1 and NF-κB p65 expression in vivo. Notes: Immunofluorescence images showed that the expression of SIRT1 was decreased and p65 acetylation was increased in DKD group mice glomerulus compared with NC group mice glomerulus and that AS-IV treatment increased SIRT1 expression and decreased p65 acetylation expression in glomerulus. Abbreviations: AS-IV, Astragaloside IV; DKD, diabetic kidney disease; NC, normal control.
Figure 3 Effect of AS-IV on SIRT1 and NF-κB p65 expression in vivo. Notes: Immunofluorescence images showed that the expression of SIRT1 was decreased and p65 acetylation was increased in DKD group mice glomerulus compared with NC group mice glomerulus and that AS-IV treatment increased SIRT1 expression and decreased p65 acetylation expression in glomerulus. Abbreviations: AS-IV, Astragaloside IV; DKD, diabetic kidney disease; NC, normal control.CC BY-NC · PubMed Central
Figure 4 Effect of AS-IV on SIRT1-induced inactivation of NF-κB signaling results in autophagy in hyperglycemia-induced MCs activation. Notes: (A and B) Real-time PCR and Western blotting results showed that both SIRT1 activator SRT1720 and AS-IV increased the level of autophagy markers (Beclin 1 and LC3 II) in MCs exposed to hyperglycemia for 48 hours, and that SIRT1 inhibitor EX527 abolished the change of AS-IV. Data are presented as mean ± SD; n=3. *Compared with co-treated with hyperglycemia and AS-IV group, P<0.05. #Compared with HG group, P<0.05. (C and D) Western blotting results showed that AS-IV treatment increased the expression of Beclin 1 and LC3 II in renal tissues compared to the untreated DKD mice. Data are presented as mean ± SD; n=3. *Compared with NC group, P<0.05. #Compared with DKD group, P<0.05. Abbreviations: AS-IV, Astragaloside IV; DKD, diabetic kidney disease; HG, high glucose; MC, mesangial cell; NC, normal control.
Figure 4 Effect of AS-IV on SIRT1-induced inactivation of NF-κB signaling results in autophagy in hyperglycemia-induced MCs activation. Notes: (A and B) Real-time PCR and Western blotting results showed that both SIRT1 activator SRT1720 and AS-IV increased the level of autophagy markers (Beclin 1 and LC3 II) in MCs exposed to hyperglycemia for 48 hours, and that SIRT1 inhibitor EX527 abolished the change of AS-IV. Data are presented as mean ± SD; n=3. *Compared with co-treated with hyperglycemia and AS-IV group, P<0.05. #Compared with HG group, P<0.05. (C and D) Western blotting results showed that AS-IV treatment increased the expression of Beclin 1 and LC3 II in renal tissues compared to the untreated DKD mice. Data are presented as mean ± SD; n=3. *Compared with NC group, P<0.05. #Compared with DKD group, P<0.05. Abbreviations: AS-IV, Astragaloside IV; DKD, diabetic kidney disease; HG, high glucose; MC, mesangial cell; NC, normal control.CC BY-NC · PubMed Central
Figure 5 Effect of AS-IV-induced autophagy on hyperglycemia-activated MCs. Notes: (A) CCK-8 assay results showed that both autophagy activator rapamycin and AS-IV (100 µM) decreased the proliferation rate in MCs exposed to hyperglycemia for 48 hours and that autophagy inhibitor 3-MA abolished the change of AS-IV. (B–D) Real-time PCR and Western blotting results showed AS-IV (100 µM) decreased the relative α-SMA levels in MCs exposed to hyperglycemia for 48 hours and that autophagy 3-MA abolished this effect. (E and F) ELISA assay results showed AS-IV (100 µM) decreased the levels of FN and Col IV in hyperglycemia-stimulated MCs for 48 hours and that 3-MA reversed this change. Data are presented as mean ± SD; n=3. *Compared with co-treated with hyperglycemia and AS-IV group, P<0.05. #Compared with HG group, P<0.05. Abbreviations: AS-IV, Astragaloside IV; HG, high glucose; MC, mesangial cell.
Figure 5 Effect of AS-IV-induced autophagy on hyperglycemia-activated MCs. Notes: (A) CCK-8 assay results showed that both autophagy activator rapamycin and AS-IV (100 µM) decreased the proliferation rate in MCs exposed to hyperglycemia for 48 hours and that autophagy inhibitor 3-MA abolished the change of AS-IV. (B–D) Real-time PCR and Western blotting results showed AS-IV (100 µM) decreased the relative α-SMA levels in MCs exposed to hyperglycemia for 48 hours and that autophagy 3-MA abolished this effect. (E and F) ELISA assay results showed AS-IV (100 µM) decreased the levels of FN and Col IV in hyperglycemia-stimulated MCs for 48 hours and that 3-MA reversed this change. Data are presented as mean ± SD; n=3. *Compared with co-treated with hyperglycemia and AS-IV group, P<0.05. #Compared with HG group, P<0.05. Abbreviations: AS-IV, Astragaloside IV; HG, high glucose; MC, mesangial cell.CC BY-NC · PubMed Central
Figure 6 Effect of AS-IV on renal function and renal morphology in diabetic KK-Ay mice. Notes: (A and B) The data showed AS-IV treatment decreased ACR and mAlb compared to the untreated DKD mice. (C) Light and electron microscopy images showed that AS-IV treatment decreased the thickness of GBM and reduced mesangial expansion, proliferation, and ECM protein overproduction compared to the untreated DKD mice. Data are presented as mean ± SD; n=3. *Compared with NC group, P<0.05. #Compared with DKD group, P<0.05. The dotted yellow boxes indicate the GBM. Abbreviations: ACR, albumin creatinine ratio; AS-IV, Astragaloside IV; DKD, diabetic kidney disease; ECM, extracellular matrix; EM, electron microscopy; GBM, glomerular basement membrane; HE, hematoxylineosin; mAlb, microalbuminuria; NC, normal control.
Figure 6 Effect of AS-IV on renal function and renal morphology in diabetic KK-Ay mice. Notes: (A and B) The data showed AS-IV treatment decreased ACR and mAlb compared to the untreated DKD mice. (C) Light and electron microscopy images showed that AS-IV treatment decreased the thickness of GBM and reduced mesangial expansion, proliferation, and ECM protein overproduction compared to the untreated DKD mice. Data are presented as mean ± SD; n=3. *Compared with NC group, P<0.05. #Compared with DKD group, P<0.05. The dotted yellow boxes indicate the GBM. Abbreviations: ACR, albumin creatinine ratio; AS-IV, Astragaloside IV; DKD, diabetic kidney disease; ECM, extracellular matrix; EM, electron microscopy; GBM, glomerular basement membrane; HE, hematoxylineosin; mAlb, microalbuminuria; NC, normal control.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

Metadata

Authors
Wang, X., Gao, Y., Tian, N., Zhu, Z., Wang, T., Xu, J., Wu, B., & Zhang, N.
Affiliations
Capital Medical University (CN)
Corresponding author
Gao, Yanbin
Venue
Drug Design, Development and Therapy
Published
2018-09
Volume
Volume 12
Pages
2971-2980
ISSN
1177-8881 (ISSN-L)
OpenAlex
W2890948470
Cited by
63
References
35
Citations by year
2026: 6 · 2025: 6 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 7 · 2020: 8 · 2019: 6
FWCI
4.30
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
National Key Research and Development Program of China (2012CB518602)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
astragaloside IV, mesangial cell activation, autophagy, SIRT1, NF-κB p65 acetylation, diabetic nephropathy, hyperglycemia, renal fibrosis, glomerular disease, SRT1720, EX527, rapamycin, 3-methyladenine
MeSH terms
Acetylation, Animals, Autophagy, Cells, Cultured, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Disease Models, Animal, Dose-Response Relationship, Drug, Glucose, Male, Mice, Inbred C57BL, Saponins, Structure-Activity Relationship, Triterpenes, Cell Proliferation, Mesangial Cells, Mice, Transcription Factor RelA, Sirtuin 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.